Addition of suberoylanilide hydroxamic acid (Vorinostat) to azacitidine for patients with higher risk myelodysplastic syndromes and azacitidine failure: a phase II add‐on study from the Groupe Francophone des Myelodysplasies

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2141|180|5|735-737

ISSN： 0007-1048

Source： BRITISH JOURNAL OF HAEMATOLOGY, Vol.180, Iss.5, 2018-03, pp. : 735-737

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-06 ,pp. : 40-48

Karger

Access to resources Recommend Favorite

Double epigenetic modulation of high‐dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor‐risk relapsed lymphoma

By  

CANCER, Vol. 122, Iss. 17, 2016-09 ,pp. : 2680-2688

John Wiley & Sons Inc

Access to resources Recommend Favorite

A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 9, 2015-09 ,pp. : 796-799

John Wiley & Sons Inc

Access to resources Recommend Favorite

Real‐life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 89, Iss. 5, 2014-05 ,pp. : 565-565

John Wiley & Sons Inc

Access to resources Recommend Favorite

Necrotizing fasciitis in two patients with myelodysplastic syndrome treated with azacitidine

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 273-276

John Wiley & Sons Inc

Access to resources Recommend Favorite